Evaluation of Hemostatic Agents in Robotic-assisted Laparoscopic Partial Nephrectomy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03528057|
Recruitment Status : Withdrawn (Difficulty recruiting participants.)
First Posted : May 17, 2018
Last Update Posted : July 5, 2019
|Condition or disease||Intervention/treatment||Phase|
|Robotic-Assisted Laparoscopic Partial Nephrectomy Hemostatic Agents Renal Malignant Tumor||Device: Hemostat||Not Applicable|
Partial nephrectomy is a surgical procedure wherein a diseased segment of a kidney is surgically removed, leaving behind the remaining healthy kidney parenchyma. This surgical procedure is typically performed to remove mass lesions suspicious for malignancy. A major goal of partial nephrectomy is to spare as much renal function as possible by preserving the healthy portion of the kidney while removing only the pathologic portion of the kidney.
Hemostatic agents (HA) are devices commonly used during robotic-assisted laparoscopic partial nephrectomy (RALPN) due to the risk of bleeding posed by incising a highly vascular organ. The use of various HAs as part of the surgical technique for RALPN is well-described. Potential benefits such as lower blood loss, lower rate of urine leak, and lower blood product transfusion rates have been suggested in small case series. However, larger prospective studies have failed to demonstrate these benefits of HAs. They report similar patient outcomes regardless of HA use. However, these studies are subject to selection bias given the lack of randomization, and they had a small relative number of partial nephrectomies performed without HAs.
To the knowledge of the investigators, no randomized trials have addressed the use of HAs in RALPN. Randomized, controlled trials for partial hepatectomy and knee arthroplasty have shown no benefit when using hemostatic agents to control bleeding.
At the home institution for this study, surgeons routinely use HAs in the resection bed during RALPN. Available, FDA approved, commercial agents include Floseal and Nu-Knit®. Each unit of HA costs $150 - $419 per unit, and often multiple units are used during a given procedure. The hospital is paid a set amount based on the patient's insurance for performing the procedure regardless of use of HA. The use of HAs therefore increases costs incurred by the hospital when performing these procedures. It is imperative to determine if this expenditure is justified.
The primary aim of this study is to compare surgical outcomes in patients undergoing RALPN with and without the use of hemostatic agents. Given the small nature of and conflicting information from the aforementioned cohort studies, it is imperative to remove selection bias and perform a randomized comparison of HA use. This study will provide a much more definitive head-to-head comparison of the overall utility of HAs. Additionally, it may provide more information about differential patient selection for more appropriate and judicious use of HAs. No study has evaluated differential patient selection for HA use, and therefore any finding in this realm would be novel.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Masking Description:||The surgical team and the patient will be blinded as to which arm the patient will be assigned both at the time of recruitment in the clinic and at the start of surgery. The patient and surgeon will both be blinded at the start of the surgery (RALPN). The surgeon will be informed intra-operatively during the renorrhaphy portion of the procedure as to which arm the patient will be assigned, at which point he will be un-blinded. Following completion of the entire surgery, the patient will also be informed as to which arm he/she was randomized upon request.|
|Official Title:||Randomized, Prospective Evaluation of Hemostatic Agents in Robotic-assisted Laparoscopic Partial Nephrectomy|
|Actual Study Start Date :||April 18, 2018|
|Estimated Primary Completion Date :||May 2019|
|Estimated Study Completion Date :||June 2020|
Active Comparator: Group 1
Patients undergoing RALPN with the use of HAs by a surgeon.
Hemostatic agents, if used at all during surgery, will be applied laparoscopically into the tumor bed to stop bleeding. The type of hemostat will be decided by the surgeon according to the anatomy of the tumor bed.
No Intervention: Group 2
Patients undergoing RALPN without the use of HAs by a surgeon
- Absolute change in hemoglobin [ Time Frame: Morning after surgery ]This will be measured as the difference between the hemoglobin obtained postoperatively (measured at approximately 4 am in the morning after surgery) and the hemoglobin obtained preoperatively in the holding area on the day of surgery.
- Total number of major bleeding complications [ Time Frame: 30 days following surgery ]Major complications are blood loss requiring transfusion of packed red blood cells, reoperation, and endovascular ablation
- Safety monitoring parameters [ Time Frame: 30 days following surgery ]Incidence of any of the following: urine leak, stroke, cardiac arrest, myocardial infarction, and death.
- Operating room parameters [ Time Frame: Total duration of surgery ]The number of sutures used during renorrhaphy and capsular closure.
- Operating room parameters [ Time Frame: Total duration of surgery ]Duration of renorrhaphy.
- Operating room parameters [ Time Frame: Total duration of surgery ]Number of patients in Group 2 (no HA) who required HA at the surgeon's discretion.
- Total length of in-patient hospital stay [ Time Frame: 30 days following surgery ]Total length of all inpatient hospital stay over 30 days measured in days.
- Total charges [ Time Frame: 30 days following surgery ]Total charges for all inpatient care over 30 days using billing information recorded in the Northwestern Electronic Data Warehouse.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03528057
|United States, Illinois|
|Northwestern Memorial Hospital|
|Chicago, Illinois, United States, 60611|
|Principal Investigator:||Robert Nadler, MD||Professor of Urology, Feinberg School of Medicine|